What does VANDAELE PHARMA do?

VANDAELE PHARMA is a pharmacy in Aalter. Private Limited, started on 15 September 2008, 2 establishments.

What is the address of VANDAELE PHARMA?

The registered office of VANDAELE PHARMA is located at Brugstraat 136, 9880 Aalter.

Is VANDAELE PHARMA still active?

Yes. According to the CBE (31 October 2026) VANDAELE PHARMA is active, legal situation “Normale toestand”, started on 15 September 2008.

Is VANDAELE PHARMA registered on Peppol?

Yes, VANDAELE PHARMA is registered on the Peppol network with ID 0208:0806355852.

What is the enterprise number of VANDAELE PHARMA?

The enterprise number of VANDAELE PHARMA is BE0806355852.

When was VANDAELE PHARMA founded?

VANDAELE PHARMA was founded on 15 September 2008.

Who are the directors of VANDAELE PHARMA?

According to the 2025 annual accounts, the directors of VANDAELE PHARMA are: HAKAPHAR BV, VANDAELE GUIDO BV.

Is VANDAELE PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 15 September 2008; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account; 2 establishments in the CBE.

How much profit did VANDAELE PHARMA make in 2025?

VANDAELE PHARMA posted a profit after taxes of € 53,941 in financial year 2025.

What is the revenue of VANDAELE PHARMA?

As a small company, VANDAELE PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 254,969.

How much does an employee at VANDAELE PHARMA earn?

The average wage cost per full-time employee at VANDAELE PHARMA was € 58,300 in 2025: staff costs of € 110,676 for 1.9 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does VANDAELE PHARMA have?

According to the 2025 annual accounts, VANDAELE PHARMA has 1.9 full-time equivalents (FTE).

VANDAELE PHARMA (Private Limited) - Aalter - BE0806355852

Dossier VANDAELE PHARMA, printed on 31 October 2026 from databakkes.be/en/0806355852/vandaele-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 56 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

VANDAELE PHARMA from Aalter, company number BE0806355852, closed financial year 2025 with a result of € 53,941 after tax. For that financial year VANDAELE PHARMA recorded a gross margin of € 254,969 and equity of € 320,048. Compared with financial year 2024, the result moved from € 113,025 to € 53,941. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on March 18, 2026.

What it is worth Growing

€ 320,048

▲ 20% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 53,941

▼ 52% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 152,000

▼ 14% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 301,448.

People and assets in 2025

Full-time equivalents

1.9

▲ 0.3 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 110,676

▲ 3% vs 2024

€ 58,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 22,083

▲ 96% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 9 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 547,727

€ 57,853 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.

Owed to suppliers

€ 101,929

▼ 8% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 17,393

▲ 19% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 190,736 Gross margin 2022: € 190,736 First fiscal year in the series	€ 183,963 Gross margin 2023: € 183,963 ▼ 4% vs 2022 (€ 190,736) Unfavourable step	€ 249,456 Gross margin 2024: € 249,456 ▲ 36% vs 2023 (€ 183,963) Favourable step	€ 254,969 Gross margin 2025: € 254,969 ▲ 2% vs 2024 (€ 249,456) Favourable step	▲ 2%
Profit after taxes	€ 149,674 Profit after taxes 2022: € 149,674 First fiscal year in the series	€ 88,385 Profit after taxes 2023: € 88,385 ▼ 41% vs 2022 (€ 149,674) Unfavourable step	€ 113,025 Profit after taxes 2024: € 113,025 ▲ 28% vs 2023 (€ 88,385) Favourable step	€ 53,941 Profit after taxes 2025: € 53,941 ▼ 52% vs 2024 (€ 113,025) Unfavourable step	▼ 52%
Equity	€ 265,347 Equity 2022: € 265,347 First fiscal year in the series	€ 265,582 Equity 2023: € 265,582 Unchanged (€ 265,347) Favourable step	€ 266,107 Equity 2024: € 266,107 Unchanged (€ 265,582) Favourable step	€ 320,048 Equity 2025: € 320,048 ▲ 20% vs 2024 (€ 266,107) Favourable step	▲ 20%
Total debts	€ 243,479 Total debts 2022: € 243,479 First fiscal year in the series	€ 240,155 Total debts 2023: € 240,155 ▼ 1% vs 2022 (€ 243,479) Favourable step	€ 403,017 Total debts 2024: € 403,017 ▲ 68% vs 2023 (€ 240,155) Unfavourable step	€ 1,040,425 Total debts 2025: € 1,040,425 ▲ 158% vs 2024 (€ 403,017) Unfavourable step	▲ 158%
Cash	€ 238,203 Cash 2022: € 238,203 First fiscal year in the series	€ 197,704 Cash 2023: € 197,704 ▼ 17% vs 2022 (€ 238,203) Unfavourable step	€ 176,326 Cash 2024: € 176,326 ▼ 11% vs 2023 (€ 197,704) Unfavourable step	€ 152,000 Cash 2025: € 152,000 ▼ 14% vs 2024 (€ 176,326) Unfavourable step	▼ 14%
Retained profit	€ 246,747 Retained profit 2022: € 246,747 First fiscal year in the series	€ 246,982 Retained profit 2023: € 246,982 Unchanged (€ 246,747) Favourable step	€ 247,507 Retained profit 2024: € 247,507 Unchanged (€ 246,982) Favourable step	€ 301,448 Retained profit 2025: € 301,448 ▲ 22% vs 2024 (€ 247,507) Favourable step	▲ 22%
Dividend	€ 149,500 Dividend 2022: € 149,500 First fiscal year in the series	€ 88,150 Dividend 2023: € 88,150 ▼ 41% vs 2022 (€ 149,500) Unchanged	€ 112,500 Dividend 2024: € 112,500 ▲ 28% vs 2023 (€ 88,150) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 112,500) Unchanged	▼ 100%
Bank debt	€ 7,798 Bank debt 2022: € 7,798 First fiscal year in the series	€ 3,135 Bank debt 2023: € 3,135 ▼ 60% vs 2022 (€ 7,798) Favourable step	€ 0 Bank debt 2024: € 0 ▼ 100% vs 2023 (€ 3,135) Favourable step	€ 547,727 Bank debt 2025: € 547,727 Unchanged (€ 0) Unfavourable step
Balance sheet total	€ 508,827 Balance sheet total 2022: € 508,827 First fiscal year in the series	€ 505,737 Balance sheet total 2023: € 505,737 ▼ 1% vs 2022 (€ 508,827) Unchanged	€ 669,124 Balance sheet total 2024: € 669,124 ▲ 32% vs 2023 (€ 505,737) Unchanged	€ 1,360,474 Balance sheet total 2025: € 1,360,474 ▲ 103% vs 2024 (€ 669,124) Unchanged	▲ 103%
Employees (FTE)	0.5 Employees (FTE) 2022: 0.5 First fiscal year in the series	1.1 Employees (FTE) 2023: 1.1 ▲ 0.6 vs 2022 (0.5) Unchanged	1.6 Employees (FTE) 2024: 1.6 ▲ 0.5 vs 2023 (1.1) Unchanged	1.9 Employees (FTE) 2025: 1.9 ▲ 0.3 vs 2024 (1.6) Unchanged	▲ 0.3

Key figures of VANDAELE PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to VANDAELE PHARMA?

What happened at VANDAELE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Mar 18, 2026 New annual accounts for financial year 2025: profit of € 53,941 (▼ 52% vs 2024). Source: NBB ↗
Jan 1, 2026 New establishment in Tielt. KBO
2020 HAKAPHAR BV became a director. NBB
2015 VANDAELE GUIDO BV became a director. NBB
Oct 1, 2008 New establishment in Aalter. KBO
Sep 15, 2008 Start of the company according to the CBE. KBO

In short

From € 149,674 profit in 2022 to € 53,941 profit in 2025.

Paid € 4,082 in corporate taxes since 2022.

Best year ever: 2022, with € 149,674 profit.

On average € 134,200 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

HAKAPHAR 90%

The stake of HAKAPHAR comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

VANDAELE PHARMA

Behind VANDAELE PHARMA are HAKAPHAR BV and VANDAELE GUIDO BV. The shares are held by HAKAPHAR (90%).

Directors

According to the 2025 annual accounts

HAKAPHAR BV

Director · represented by Karel Vandaele

Also active at: VANDAELE GUIDO, VANDAPHAR

since 2020

VANDAELE GUIDO BV

Director · represented by Vandaele Guido

since 2015

Shareholders

HAKAPHAR

90%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Brugstraat 136

9880 Aalter

2.385.868.616

Jules Van Ooststraat 25

8700 Tielt

Active since 1 January 2026

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

HAKAPHAR same network

€ 153,112 gross margin · 2025

VANDAPHAR same network

€ 63,572 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0806.355.852

VAT number

BE 0806.355.852

Registered office

Brugstraat 136, 9880 Aalter

Names & denominations

VANDAELE PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

15 September 2008

Peppol

Active · Active since 28 Jul 2025

Activities · NACE

Apotheken

Overige dienstverlenende activiteiten op het gebied van informatie

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Overige dienstverlenende activiteiten op het gebied van informatie, n.e. g.

Detailhandel in drogisterijartikelen en onderhoudsproducten

Detailhandel in corrigerende brillen, lenzen en zonnebrillen

Detailhandel in cosmetica en toiletartikelen

View on CBE Public ↗ Annual accounts (NBB) ↗

VANDAELE PHARMA

Warning lights

Financials

What happened to VANDAELE PHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions